Submit to Special Issue Submit Abstract to Special Issue Review for Pharmaceutics Edit a Special Issue

Journal Menu

Journal Browser

Special Issue "Advances in Parenteral Formulations"

Print Special Issue Flyer
Special Issue Editors
Special Issue Information
Keywords
Published Papers

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".

Deadline for manuscript submissions: 10 August 2023 | Viewed by 3970

Share This Special Issue

Special Issue Editors

Prof. Dr. Anna Jelińska

E-Mail Website
Guest Editor

Department of Pharmaceutical Chemistry, Poznan University of Medical Sciences, 60-780 Poznan, Poland
Interests: drug analysis; drug stability; pharmaceutical chemistry
Special Issues, Collections and Topics in MDPI journals

Dr. Maciej Stawny

E-Mail Website
Guest Editor

Department of Pharmaceutical Chemistry, Poznan University of Medical Sciences, 60-780 Poznan, Poland
Interests: drug interactions; parenteral nutrition; hospital pharmacy; nanotechnology
Special Issues, Collections and Topics in MDPI journals

Dr. Katarzyna Dettlaff

E-Mail Website
Guest Editor

Department of Pharmaceutical Chemistry, Poznan University of Medical Sciences, 60-780 Poznan, Poland
Interests: drug analysis; drug stability; parenteral nutrition; radiation sterilization

Special Issue Information

Dear Colleagues,

In recent years, there has been great progress in the field of parenteral drugs. This is due to the development of pharmaceutical technology and drug analysis as a response to the emergence of clinical challenges.

The crucial issue in parenteral formulation is chemical, physical, and microbiological stability. One of the biggest problems of the technological process of such drugs is the poor solubility and permeability of most active pharmaceutical ingredients. To overcome this disadvantage, nanotechnology is used, including lipid-based, polymeric, and hybrid nanoparticles. Prolonged drug release formulations are developed, such as in situ implants and drug carriers enabling the drug to reach a critical organ or neoplastic tumor.

Other important issues related to parenteral drugs are their safety, PK/PD interactions, and drug compatibility when administered simultaneously through the same vascular access.

This Special Issue in Pharmaceutics is dedicated to the advantages of parenteral formulations and aims to draw together experts in the fields of pharmaceutical sciences, technology, analytical chemistry, and clinical medicine. Authors are invited to submit original and review articles covering all aspects of this important research field. We look forward to receiving your contributions.

Prof. Dr. Anna Jelińska
Dr. Maciej Stawny
Dr. Katarzyna Dettlaff
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

nanoparticle
drug interactions
nanoemulsions and submicron emulsions
drug carriers
drug compatibility
parenteral nutrition

Published Papers (3 papers)

Download All Papers

Order results

Result details

Show export options Show export options

Select all

Export citation of selected articles as:

Research

Open AccessArticle

Y-Site Compatibility Studies of Ketoprofen with Parenteral Nutrition Admixtures for Central and Peripheral Administration

and

Pharmaceutics 2022, 14(12), 2570; https://doi.org/10.3390/pharmaceutics14122570 - 23 Nov 2022

Viewed by 717

Abstract

Ketoprofen (KTF) is often used in hospital wards, especially in its intravenous form. According to the literature review, the compatibility of ketoprofen with parenteral nutrition (PN) admixtures has not yet been investigated. For this reason, we aimed to provide data contributing to physical compatibility to ensure the safe co-administration of these medications. In this study, we examined the compatibility of KTF with eight selected commercial PN admixtures intended for central (Lipoflex Special, Omegaflex Special, Kabiven, SmofKabiven) and peripheral (Lipoflex peri, Omegaflex peri, Kabiven Peripheral, Olimel Peri N4E) administration. The KTF solution for infusion was combined in three different volume ratios with studied PN admixtures reflecting the conditions in clinical practice. The evaluation of undesirable physical destabilization of oil-in-water system or precipitate formation involved the visual inspection and the determination of mean droplet diameter, zeta potential, pH, and turbidity changes. The results of compatibility of KTF with eight commercial PN admixtures showed that three of them: Kabiven, SmofKabiven, and Kabiven Peripheral, are incompatible with KTF and should not be concomitantly administered. Full article

(This article belongs to the Special Issue Advances in Parenteral Formulations)

► Show Figures

Figure 1

Open AccessArticle

Behavior of Regular Insulin in a Parenteral Nutrition Admixture: Validation of an LC/MS-MS Assay and the In Vitro Evaluation of Insulin Glycation

Heloise Henry

Jean-François Goossens

and

Pharmaceutics 2022, 14(5), 1081; https://doi.org/10.3390/pharmaceutics14051081 - 18 May 2022

Cited by 1 | Viewed by 1049

Abstract

Parenteral-nutrition (PN)-induced hyperglycemia increases morbidity and mortality and must be treated with insulin. Unfortunately, the addition of insulin to a ternary PN admixture leads to a rapid decrease in insulin content. Our study’s objective was to determine the mechanistic basis of insulin’s disappearance. The literature data suggested the presence of a glycation reaction; we therefore validated an LC-MS/MS assay for insulin and glycated insulin. In a 24-h stability study, 20 IU/L of insulin was added to a binary PN admixture at pH 3.6 or 6.3. When the samples were diluted before analysis with a near-neutral diluent, insulin was fully stable at pH 3.6, while a loss of around 50% was observed at pH 6.3. Its disappearance was shown to be inversely correlated with the appearance of monoglycated insulin (probably a Schiff base adduct). Monoglycated insulin might also undergo a back-reaction to form insulin after acidic dilution. Furthermore, a second monoglycated insulin species appeared in the PN admixture after more than 24 h at high temperature (40 °C) and a high insulin concentration (1000 IU/L). It was stable at acidic pH and might be an Amadori product. The impact of insulin glycation under non-forced conditions on insulin’s bioactivity requires further investigation. Full article

(This article belongs to the Special Issue Advances in Parenteral Formulations)

► Show Figures

Graphical abstract

Open AccessArticle

Sodium Valproate Incompatibility with Parenteral Nutrition Admixtures—A Risk to Patient Safety: An In Vitro Evaluation Study

and

Pharmaceutics 2022, 14(2), 371; https://doi.org/10.3390/pharmaceutics14020371 - 07 Feb 2022

Cited by 1 | Viewed by 1475

Abstract

Epilepsy is defined as a group of concerning problems related to the nervous system; its defining feature is a predisposition to epileptic seizures. The frequency of seizures in intensive care units (ICU) ranges from 3.3% to 34%, and ICU antiepileptic treatment is routine practice. The administration of drugs through the same infusion line is not recommended but is common clinical practice, especially in ICU. Incompatibilities between parenteral drugs and between drugs and parenteral nutrition admixtures (PNAs) are common medical errors and pose risks to patient safety. The co-administration of drugs must always be confirmed and clearly defined. The simultaneous infusion of sodium valproate (VPA, drug used to treat seizures and epilepsy) with parenteral PNAs has not yet been studied. During the experiment reported in this study, a visual control, pH, osmolality, zeta potential, particle size, polydispersity index, and turbidity were measured. The conducted research shows that the lipid emulsion composition has a significant influence on drug–PN (drug–parenteral nutrition) compatibility. The acceptance criteria were met only for PNs containing omega-3-acid-triglycerides (Omegaflex special and peri). The second fraction of particles above 1000 nm was observed for most of the tested PNAs (Lipoflex special, Lipoflex peri, Kabiven, SmofKabiven, Kabiven Peripheral, and Olimel Peri N4E), which disqualifies their simultaneous administration with VPA. Full article

(This article belongs to the Special Issue Advances in Parenteral Formulations)

► Show Figures

Journal Menu

Journal Browser

Special Issue "Advances in Parenteral Formulations"

Share This Special Issue

Special Issue Editors

Special Issue Information

Keywords

Published Papers (3 papers)

Research

Further Information

Guidelines

MDPI Initiatives

Follow MDPI